Travere Therapeutics, Inc. (TVTX)
52.30
+1.81
(+3.58%)
USD |
NASDAQ |
Oct 20, 16:00
52.26
-0.04
(-0.08%)
After-Hours: 20:00
Travere Therapeutics Research and Development Expense (TTM) : 227.14M for June 30, 2026
Research and Development Expense (TTM) Chart
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | 227.14M |
| March 31, 2026 | 216.22M |
| December 31, 2025 | 206.01M |
| September 30, 2025 | 210.21M |
| June 30, 2025 | 210.00M |
| March 31, 2025 | 214.96M |
| December 31, 2024 | 217.50M |
| September 30, 2024 | 214.18M |
| June 30, 2024 | 220.64M |
| March 31, 2024 | 233.30M |
| December 31, 2023 | 239.65M |
| September 30, 2023 | 236.54M |
| June 30, 2023 | 233.10M |
| March 31, 2023 | 224.16M |
| December 31, 2022 | 224.72M |
| September 30, 2022 | 230.95M |
| June 30, 2022 | 224.37M |
| March 31, 2022 | 217.83M |
| December 31, 2021 | 209.17M |
| September 30, 2021 | 185.39M |
| June 30, 2021 | 169.33M |
| March 31, 2021 | 148.31M |
| December 31, 2020 | 130.61M |
| September 30, 2020 | 128.59M |
| June 30, 2020 | 129.46M |
| Date | Value |
|---|---|
| March 31, 2020 | 136.61M |
| December 31, 2019 | 139.80M |
| September 30, 2019 | 135.43M |
| June 30, 2019 | 134.66M |
| March 31, 2019 | 131.19M |
| December 31, 2018 | 122.56M |
| September 30, 2018 | 110.35M |
| June 30, 2018 | 97.72M |
| March 31, 2018 | 82.96M |
| December 31, 2017 | 79.20M |
| September 30, 2017 | 79.70M |
| June 30, 2017 | 78.52M |
| March 31, 2017 | 76.71M |
| December 31, 2016 | 70.52M |
| September 30, 2016 | 65.90M |
| June 30, 2016 | 61.42M |
| March 31, 2016 | 54.19M |
| December 31, 2015 | 49.75M |
| September 30, 2015 | 48.74M |
| June 30, 2015 | 47.64M |
| March 31, 2015 | 50.71M |
| December 31, 2014 | 47.34M |
| September 30, 2014 | 38.66M |
| June 30, 2014 | 27.30M |
| March 31, 2014 | 14.46M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (TTM) Benchmarks
| TG Therapeutics, Inc. | 225.80M |
| BioMarin Pharmaceutical, Inc. | 766.68M |
| Vertex Pharmaceuticals, Inc. | 3.907B |
| Viridian Therapeutics, Inc. | 324.21M |
| Krystal Biotech, Inc. | 53.39M |